Connect with us
MARE BALTICUM Gaming & TECH Summit 2024

Artificial Intelligence

Liquid Biopsy Market to Perceive Highest CAGR of 15.2% by 2030, Size, Share, Trends, Key Drivers, Growth and Opportunity Analysis

Published

on

<!– Name:DistributionId Value:8845604 –> <!– Name:EnableQuoteCarouselOnPnr Value:False –> <!– Name:IcbCode Value:5377 –> <!– Name:CustomerId Value:1201301 –> <!– Name:HasMediaSnippet Value:false –> <!– Name:AnalyticsTrackingId Value:d35f067d-376d-42db-87c0-bbc112252242 –>

CHICAGO, May 24, 2023 (GLOBE NEWSWIRE) — Data Bridge Market Research has released a new report titled “Liquid Biopsy Market” which delves deep into growth strategies, drivers, opportunities, key segments, Porter’s Five Forces analysis, and competitive environment. The widespread Liquid Biopsy market report underlines the primary and secondary drivers, market share, possible sales volume, leading segments, and geographical analysis. Other key market parameters range from industry outlook with respect to critical success factors (CSFs), industry dynamics that mainly cover drivers and restraints, market segmentation & value chain analysis, key opportunities, application and technology outlook, regional or geographical insight, country-level analysis, key company profiles, competitive landscape, to company market share analysis. The liquid Biopsy market survey report carries out an evaluation of the growth rate and the market value of the Liquid Biopsy industry based on market dynamics and growth-inducing factors.

A high-ranking Liquid Biopsy report performs a thorough investigation of current scenario of the global market, which covers several market dynamics. Moreover, for the businesses, it is the most important to get knowhow of consumer’s demands, preferences, attitudes and their changing tastes about the specific product which can be studied via this report. To get knowledge of all the above things, this market report is made transparent, wide-ranging and supreme in quality. The credible Liquid Biopsy market report is prepared with the detailed market analysis performed by a team of industry experts, skilful analysts, dynamic forecasters and knowledgeable researchers.

Data Bridge Market Research analyzes that the global liquid biopsy market will grow at a CAGR of 15.2% during the forecast period of 2023 to 2030.

Get Sample PDF of the Liquid Biopsy Market @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-liquid-biopsy-market

A liquid biopsy is a medical test that involves the analysis of various biomolecules, such as DNA, RNA, proteins, and other substances in a patient’s blood or other bodily fluids, to diagnose and monitor various medical conditions, including cancer. Unlike traditional biopsies that involve the removal of tissue samples from the body, a liquid biopsy is non-invasive and can provide important diagnostic information without the need for surgery or other invasive procedures. Liquid biopsies are still in the early stages of development but hold promise for improving the detection and management of cancer and other diseases.

The global liquid biopsy market is expected to grow in the forecast year due to the rise in market players and the availability of advanced services. Along with this, manufacturers are engaged in the developmental activity for launching novel services in the market. The increasing development in the field of advanced healthcare techniques is further boosting market growth.

However, difficulties such as the lack of standardized protocols and the lack of skilled professionals might hamper the growth of the global liquid biopsy market in the forecast period.

The Latest Study Conducts a Comprehensive Analysis of the Global Market, considering the current competitive landscape and its future evolution in the next few years.

The global Liquid Biopsy market is experiencing rapid growth, fueled by rising demands, industrialization, consumer awareness, and technological advancements. Sales and revenue in this sector have surged at an exponential pace, and the market’s expansion is expected to continue over the projected period.

In order to expand their market share and reach a wider client base, leading businesses in the worldwide Liquid Biopsy market are heavily investing in research and development. The study provides detailed insights into the strategies, financial health, revenue, gross margin, and growth rates of these companies.

The most prominent players in the Liquid Biopsy market include.

  • F. Hoffmann-La Roche Ltd
  • Guardant Health
  • Thermo Fisher Scientific Inc.
  • Exact Sciences Corporation (Genomic health)
  • Johnson & Johnson Services, Inc.
  • Illumina Inc
  • NeoGenomics Laboratories
  • Bio-Rad Laboratories, Inc.
  • Natera, Inc.
  • CARDIFF ONCOLOGY, INC.
  • Menarini Silicon Biosystems
  • Biocept, Inc.
  • Sysmex Inostics Inc.
  • Fluxion Biosciences Inc
  • Epic Sciences
  • Oncocyte Corporation

Recent Development

  • In January 2022, Exact Sciences Corporation announced the acquisition of Prevention Genetics, a genetic testing laboratory, to complement its advanced cancer diagnostics portfolio and support its entrance into hereditary cancer testing (HCT).

Click Here to Download the Complete Research Study in PDF Format @ https://www.databridgemarketresearch.com/checkout/buy/enterprise/global-liquid-biopsy-market

The report includes seven parts, dealing with:

  1. Basic information
  2. The Asia Pacific Liquid Biopsy Market
  3. The North America Liquid Biopsy Market
  4. The Europe Liquid Biopsy Market
  5. MEA Liquid Biopsy Market
  6. Market entry and investment feasibility
  7. The report conclusion

All the research report is made by using two techniques that are Primary and secondary research. There are various dynamic features of the business, like client need and feedback from the customers. Before (company name) curate any report, it has studied in-depth from all dynamic aspects such as industrial structure, application, classification, and definition.

Opportunity:

  • Integration of Artificial Intelligence (AI) and machine learning

Liquid biopsy-based approaches offer many new opportunities to measure molecular Biomakers for diagnosing, prognosis, and monitoring disease. Artificial Intelligence (AI), such as machine learning, and its ability to identify signatures of specific disease states in multiplexed data will be key to taking advantage of the new molecular information that microchip-based diagnostics can extract.

Thus, the integration of AI and machine learning is expected to act as an opportunity for the growth of the market.

  • Increasing reimbursements and government support for liquid biopsy

The adoption of liquid biopsy has been significantly influenced by government backing. Governments throughout the world have put legislation in place to encourage the adoption of liquid biopsy because they understand how it may enhance patient care, lower healthcare costs, and advance precision medicine. Incorporating liquid biopsy into national cancer screening programs or treatment recommendations is only one example of how this might be done. Other examples include financing for research and development of liquid biopsy technologies and backing clinical trials and studies to produce evidence on their therapeutic efficacy. Such government assistance has aided in boosting liquid biopsy test knowledge, adoption, and reimbursement coverage.

Thus, increasing reimbursements and government support for liquid biopsy is expected to act as an opportunity for the market’s growth.

Key Market Segments Covered in Liquid Biopsy Industry Research

Product

  • Instruments
  • Consumables & Accessories
  • Services & Software

Biomaker Type

  • Circulating Cell-Free DNA (CFDNA)
  • Cell-Free RNA
  • Extracellular vesicles

Sample Type

  • Blood Sample-Based
  • Urine Sample-Based
  • Saliva & Other Tissue Fluids Sample-Based

Analytical Type

  • Histology/Imaging

Application Type

  • Cancer Applications
  • Non-Cancer Applications

Clinical Application

  • Routine Screening
  • Therapy Selection
  • Treatment Monitoring
  • Recurrence Monitoring
  • Patient Work-Up

Technology

  • Multi-Gene-Parallel Analysis
  • Single Gene Analysis

End User

  • Reference Laboratories
  • Diagnostics Centers
  • Research Centres and Academic Institutes

Distribution Channels

  • Direct Tender
  • Third-Party Distributor

Explore Further Details about This Research Report @ https://www.databridgemarketresearch.com/reports/global-liquid-biopsy-market

Key Industry Drivers:

  • Growing demand for non-invasive liquid biopsy technique

Liquid biopsies consist of isolating tumor-derived entities such as circulating tumor cells, circulating tumor DNA, and tumor extracellular vesicles among others, present in the body fluids of patients with cancer, followed by an analysis of genomic and proteomic data contained within them. Methods for isolation and analysis of liquid biopsies have rapidly evolved over the past few years, as described in the review, thus providing greater details about tumor characteristics such as mutations, tumor staging, tumor progression, heterogeneity, and gene and clonal evolution, among others. Liquid biopsies from cancer patients have opened up newer avenues in detection and continuous monitoring, treatment based on precision medicine, and screening of markers for therapeutic resistance. Non-invasive cancer diagnostics offer a safer and more patient-friendly approach, resulting in a growing demand for these methods.

  • Advancements in precision medicine due to liquid biopsy

Precision medical oncology in the clinical management of cancer may be achieved through the diagnostic platform called “liquid biopsy” (LB). The LB was recognized as a powerful real-time approach for the molecular monitoring of this dynamic cancer disease. This method utilizes the detection of Biomakers in blood for prognostic and predictive purposes by non-invasive means, which in the near future will represent a change in the paradigm of molecular biology understanding and the heterogeneity of tumors. Advancements in precision medicine, fueled by the use of liquid biopsy techniques, have contributed significantly to the growing demand for non-invasive cancer diagnostics. Liquid biopsy techniques, such as the analysis of circulating tumor DNA (ctDNA), Circulating Tumor Cells (CTCs), or exosomes in blood or other body fluids, provide valuable information about the genetic makeup of tumors, enabling precision medicine approaches in cancer care.

Liquid Biopsy Market Regional Analysis/Insights:

The countries covered in this Liquid Biopsy Market Report U.S., Canada, Mexico, Germany, U.K., France, Italy, Spain, Netherlands, Russia, Switzerland, Turkey, Belgium, Rest of Europe, Japan, China, Australia, India, South Korea, Singapore, Indonesia, Thailand, Malaysia, Philippines, Rest of Asia-Pacific, Brazil, Argentina, and the Rest of South America, Saudi Arabia, South Africa, U.A.E., Israel, Egypt, and the rest of the Middle East and Africa.

In 2023, North America is expected to dominate the global liquid biopsy market due to the growing demand for non-invasive cancer diagnostics. Japan is expected to dominate the Asia-Pacific liquid biopsy market due to technological advancements in liquid biopsy platforms in the country.

Radical conclusions of the report:

  • Industry overview with a futuristic perspective
  • Analysis of production costs and analysis of the industrial chain
  • Full regional analysis
  • Benchmarking the competitive landscape
  • Market growth trends; current and emerging
  • Technological developments and products
  • Comprehensive coverage of market factors, restraints, opportunities, threats, limitations, and outlook for the Market
  • SWOT Analysis, Porter’s Five Forces Analysis, Feasibility Analysis, and ROI Analysis

Table of Contents:

  1. Introduction
  2. Market Segmentation
  3. Executive Summary
  4. Premium Insights
  5. Global Liquid Biopsy Market: Regulations
  6. Market Overview
  7. Global Liquid Biopsy Market, By Product
  8. Global Liquid Biopsy Market, By Biomarker Type
  9. Global Liquid Biopsy Market, By Sample Type
  10. Global Liquid Biopsy Market, By Analytical Type
  11. Global Liquid Biopsy Market, By Application Type
  12. Global Liquid Biopsy Market, By Clinical Application
  13. Global Liquid Biopsy Market, By Technology
  14. Global Liquid Biopsy Market, By End User
  15. Global Liquid Biopsy Market, By Distribution Channels
  16. Global Liquid Biopsy Market, By Region
  17. Global Liquid Biopsy Market: Company Landscape
  18. SWOT Analyses
  19. Company Profile
  20. Questionnaires
  21. Related Reports

Download the Complete Table of Contents @ https://www.databridgemarketresearch.com/toc/?dbmr=global-liquid-biopsy-market

Explore More Reports:

  • Breast Cancer Liquid Biopsy Market, By Product (Consumables, Kits), Circulating Biomarkers (Extracellular Vesicles (EVs), Cell-free DNA (cfDNA), ctRNA, Circulating Tumor Cells (CTCs), cfRNA, Others), End Users (Laboratories, Hospitals, Physician Laboratories, Reference Laboratories, Public Health Laboratories, Research Institutes, Small Molecular Laboratories, Pathology Laboratories), Country (U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia- Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, UAE, Egypt, Israel, Rest of Middle East and Africa) https://www.databridgemarketresearch.com/reports/global-breast-cancer-liquid-biopsy-market
  • Circulating Tumor Cells (CTC) Liquid Biopsy Market, By Technology (CTC Detection Methods, CTC Enrichment Methods, Ex Vivo Positive Selection, Molecular (RNA)-Based Technologies, Functional In vitro Cell Invasion Assay, Xenotransplantation Models, Microchips, Single Spiral Microchannel, Negative Selection & Immunocytochemical Technologies), Application (Cancer Stem Cell Research, Multiple Chromosome Abnormalities & Others), End User (Research & Academic Institutes, Reference Laboratories & Hospitals & Physician Laboratories), Country (U.S., Canada, Mexico, Germany, France, U.K., Italy, Spain, Russia, Turkey, Netherlands, Switzerland, Rest of Europe, Japan,  China, South Korea, India, Australia, Singapore,  Thailand, Malaysia, Indonesia, Philippines, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, UAE, Egypt, Israel and Rest of Middle East and Africa) https://www.databridgemarketresearch.com/reports/global-circulating-tumor-cells-ctc-liquid-biopsy-market
  • Europe Circulating Tumor Cells (CTC) Liquid Biopsy Market, By Technology (CTC Detection Methods, CTC Enrichment Methods, Ex Vivo Positive Selection, Molecular (RNA)-Based Technologies, Functional In vitro Cell Invasion Assay, Xenotransplantation Models, Microchips, Single Spiral Microchannel, Negative Selection & Immunocytochemical Technologies), Application (Cancer Stem Cell Research, Multiple Chromosome Abnormalities & Others), End User (Research & Academic Institutes, Reference Laboratories & Hospitals & Physician Laboratories),Country (Germany, France, U.K., Hungary, Lithuania, Austria, Ireland, Norway, Poland, Italy, Spain, Russia, Turkey, Netherlands, Switzerland’s, Rest of Europe) https://www.databridgemarketresearch.com/reports/europe-circulating-tumor-cells-ctc-liquid-biopsy-market
  • Asia-Pacific Liquid Biopsy Market, By Product (Instruments, Consumables & Accessories, Services & Software), Biomaker Type (Circulating Tumor Cells (CTCS), Circulating Cell-Free DNA (CFDNA), Cell-free RNA, Extracellular Vesicles, Exosomes, and Others), Sample Type (Blood Sample-Based, Urine Sample-Based, Saliva & Other Tissue Fluid Sample-Based, and Others), Analytical Type (Molecular, Proteomics, and Histology/Imaging), Application Type (Cancer Applications and Non-Cancer Applications), Clinical Application (Routine Screening, Patient Work-Up, Therapy Selection, Treatment Monitoring, Recurrence Monitoring, and Others), Technology (Multi-Gene Parallel Analysis, and Single-Gene Analysis), End User (Hospitals, Reference Laboratories, Diagnostic Centers, Research Centers & Academic Institutes, and Others), Distribution Channel (Direct Tender, Third Party Distributor, and Others) https://www.databridgemarketresearch.com/reports/asia-pacific-liquid-biopsy-market
  • Europe Liquid Biopsy Market, By Product (Instruments, Consumables & Accessories, Services & Software), Biomaker Type (Circulating Tumor Cells (CTCS), Circulating Cell-Free DNA (CFDNA), Cell-free RNA, Extracellular Vesicles, Exosomes, and Others), Sample Type (Blood Sample-Based, Urine Sample-Based, Saliva & Other Tissue Fluid Sample-Based, and Others), Analytical Type (Molecular, Proteomics, and Histology/Imaging), Application Type (Cancer Applications and Non-Cancer Applications), Clinical Application (Routine Screening, Patient Work-Up, Therapy Selection, Treatment Monitoring, Recurrence Monitoring, and Others), Technology (Multi-Gene Parallel Analysis, and Single-Gene Analysis), End User (Hospitals, Reference Laboratories, Diagnostic Centers, Research Centers & Academic Institutes, and Others), Distribution Channel (Direct Tender, Third Party Distributor, and Others) https://www.databridgemarketresearch.com/reports/europe-liquid-biopsy-market
  • Middle East and Africa Liquid Biopsy Market, By Product (Instruments, Consumables & Accessories, Services & Software), Biomaker Type (Circulating Tumor Cells (CTCS), Circulating Cell-Free DNA (CFDNA), Cell-free RNA, Extracellular Vesicles, Exosomes, and Others), Sample Type (Blood Sample-Based, Urine Sample-Based, Saliva & Other Tissue Fluid Sample-Based, and Others), Analytical Type (Molecular, Proteomics, and Histology/Imaging), Application Type (Cancer Applications and Non-Cancer Applications), Clinical Application (Routine Screening, Patient Work-Up, Therapy Selection, Treatment Monitoring, Recurrence Monitoring, and Others), Technology (Multi-Gene Parallel Analysis, and Single-Gene Analysis), End User (Hospitals, Reference Laboratories, Diagnostic Centers, Research Centers & Academic Institutes, and Others), Distribution Channel (Direct Tender, Third Party Distributor, and Others) https://www.databridgemarketresearch.com/reports/middle-east-and-africa-liquid-biopsy-market
  • North America Liquid Biopsy Market, By Product (Instruments, Consumables & Accessories, Services & Software), Biomaker Type (Circulating Tumor Cells (CTCS), Circulating Cell-Free DNA (CFDNA), Cell-free RNA, Extracellular Vesicles, Exosomes, and Others), Sample Type (Blood Sample-Based, Urine Sample-Based, Saliva & Other Tissue Fluid Sample-Based, and Others), Analytical Type (Molecular, Proteomics, and Histology/Imaging), Application Type (Cancer Applications and Non-Cancer Applications), Clinical Application (Routine Screening, Patient Work-Up, Therapy Selection, Treatment Monitoring, Recurrence Monitoring, and Others), Technology (Multi-Gene Parallel Analysis, and Single-Gene Analysis), End User (Hospitals, Reference Laboratories, Diagnostic Centers, Research Centers & Academic Institutes, and Others), Distribution Channel (Direct Tender, Third Party Distributor, and Others) https://www.databridgemarketresearch.com/reports/north-america-liquid-biopsy-market
  • Image-Guided Biopsy Market, By Technology (X- Ray, Ultrasound, Mammograpy, CT, MRI), Process (Fine Needle, Core Needle, Vacuum- Assisted Biopsy), End-User (Hospitals, Ambulatory Surgery Centers, Clinics, Research and Academic Institutes), Country (U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, UAE, Egypt, Israel, Rest of Middle East & Africa) https://www.databridgemarketresearch.com/reports/global-image-guided-biopsy-market
  • Vacuum-Assisted Biopsy Market By Guiding Technique (Stereotactic Vacuum Assist Biopsy System and Image Guided Vacuum Assist Biopsy System), Type (9-12G, <9G and >12G), Applications (Hospitals, Academic and Research Institutes and Diagnostics and Imaging Centres), Country (U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia- Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, UAE, Egypt, Israel, Rest of Middle East and Africa) https://www.databridgemarketresearch.com/reports/global-vacuum-assisted-biopsy-market
  • Needle Biopsy Market, By Needle Type (Trephine Biopsy Needles, Klima Sternal Needle, Salah Needle Aspiration Needle, Jamshidi Needle and Others), Ergonomics (Sharp, Blunt, Quincke, Chiba, Franseen and Others), Procedure (Fine-Needle Aspiration Biopsy, Core Needle Biopsy, Vacuum-Assisted Biopsy, Image-Guided Biopsy), Sample Site (Muscles, Bones and Other Organs), Utility (Disposable and Reusable), Application (Tumour, Infection, Inflammation and Others), End User (Hospitals, Diagnostic Centres, Biopsy Labs, Ambulatory Surgical Centres, Academic and Research Organizations and Others), Distribution Channel (Direct Tender, Retail Sales), Country (U.S., Canada, Mexico, Germany, France, U.K., Belgium, Lithuania, Austria, Ireland, Norway, Poland, Italy, Spain, Russia, Turkey, Netherlands Switzerland, Rest of Europe, Japan, China, South Korea, India, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, UAE, Egypt, Israel and Rest of Middle East and Africa) https://www.databridgemarketresearch.com/reports/global-needle-biopsy-market
  • Smart Biopsy Devices Market, By Application (Breast Cancer, Skin Cancer, Liver Cancer, Prostate Cancer, Others), Product (Needle-Based Biopsy Instruments, Procedure Trays, Localization Wires, Other Products), Guidance Technique (Ultrasound-Guided Biopsy, Stereotactic-Guided Biopsy, Magnetic Resonance Imaging-Guided Biopsy, Other Guidance Techniques), End User (Hospitals, Academic and Research Institutes, Diagnostic and Imaging Centers) Country (U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia- Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, UAE, Egypt, Israel, Rest of Middle East and Africa) https://www.databridgemarketresearch.com/reports/global-smart-biopsy-devices-market
  • Bone Marrow Biopsy Market, By Product Type (Needles, Instruments, Biopsy Gun, Procedure Trays, Others), Procedure Type (Hip Biopsy, Breastbone (Sternum) Biopsy, Percutaneous Trephine Biopsy, Tibia (Shin) Biopsy, Others), Biopsy Type (Core Needle Biopsy, Vacuum-Assisted Biopsy (VAB), Fine Needle Aspiration Biopsy), Site (Posterior Iliac Crest, Anterior Iliac Crest, Calcaneus, Distal Tibia, Proximal Tibia, Proximal Humerus, Others), Technique (Flow Cytometry, Fluorescence In Situ Hybridization (Fish), Polymerase Chain Reaction (PCR), Karyotype Test, Other), Age (Geriatric, Adult, Pediatric), Application (Lymphoma Disease, Leukemia, Polycythemia Vera, Multiple Myeloma, Thrombocythemia, Myelofibrosis, Aplastic Anemia, Others), End User (Hospitals, Diagnostic Centers, Ambulatory Surgical Centers, Academic and Research Organizations, Others) https://www.databridgemarketresearch.com/reports/global-bone-marrow-biopsy-market

About Data Bridge Market Research:

An absolute way to forecast what the future holds is to comprehend the trend today!

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with an unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to complex business challenges and initiates an effortless decision-making process. Data Bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune.

Data Bridge Market Research has over 500 analysts working in different industries. We have catered more than 40% of the Fortune 500 companies globally and have a network of more than 5000+ clientele around the globe. Data Bridge is adept in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. We are content with our glorious 99.9 % client satisfaction rate.

Contact Us:

Data Bridge Market Research
US: +1 888 387 2818
UK: +44 208 089 1725
Hong Kong: +852 8192 7475
Email:- [email protected]

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Artificial Intelligence

Oncolytics Biotech® Announces Upcoming Presentations at the American Society of Clinical Oncology Annual Meeting

Published

on

oncolytics-biotech-announces-upcoming-presentations-at-the-american-society-of-clinical-oncology-annual-meeting

SAN DIEGO and CALGARY, AB, April 25, 2024 /PRNewswire/ — Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced the acceptance of two abstracts at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, which is taking place from May 31 – June 4, 2024, in Chicago, Illinois. Details on the abstracts and poster presentation are shown below.

Title: Phase 1/2 randomized, open-label, multicenter, Simon two-stage study of pelareorep combined with modified FOLFIRINOX +/- atezolizumab in patients with metastatic pancreatic ductal adenocarcinoma.
Presentation Type: PosterAbstract Number: TPS4203Session Title: Gastrointestinal Cancer – Gastroesophageal, Pancreatic, and HepatobiliarySession Date and Time: June 1, 2024, 1:30 – 4:30 p.m. CTTitle: Pelareorep driven blood TIL expansion in patients with pancreatic, breast and colon cancer.Presentation Type: Online abstractAbstract Number: e14625
Abstracts will be published on the ASCO Annual Meeting website at 5:00 p.m. ET on May 23, 2024.
About Oncolytics Biotech Inc.
Oncolytics is a clinical-stage biotechnology company developing pelareorep, an intravenously delivered immunotherapeutic agent. Pelareorep has demonstrated promising results in two randomized Phase 2 studies in metastatic breast cancer and Phase 1 and 2 studies in pancreatic cancer. It acts by inducing anti-cancer immune responses and promotes an inflamed tumor phenotype — turning “cold” tumors “hot” — through innate and adaptive immune responses to treat a variety of cancers.
Pelareorep has demonstrated synergies with multiple approved oncology treatments. Oncolytics is currently conducting and planning combination clinical trials with pelareorep in solid and hematological malignancies as it advances towards registrational studies in metastatic breast cancer and pancreatic cancer, both of which have received Fast Track designation from the FDA. For further information, please visit: www.oncolyticsbiotech.com or follow the company on social media on LinkedIn and on X @oncolytics.
 
Company Contact
Jon Patton
Director of IR & Communication
[email protected]
 
Investor Relations for Oncolytics
Timothy McCarthy
LifeSci Advisors
+1-917-679-9282
[email protected]
 
 

View original content:https://www.prnewswire.co.uk/news-releases/oncolytics-biotech-announces-upcoming-presentations-at-the-american-society-of-clinical-oncology-annual-meeting-302127245.html

Continue Reading

Artificial Intelligence

Internet of Things (IoT) Market to Expand at a Stellar 19.4% CAGR through 2031 | SkyQuest Technology

Published

on

internet-of-things-(iot)-market-to-expand-at-a-stellar-19.4%-cagr-through-2031-|-skyquest-technology

WESTFORD, Mass., April 25, 2024 /PRNewswire/ — SkyQuest projects that the Internet of Things (IoT) Market will attain a value of USD 1572.37 billion by 2031, with a CAGR of 19.4% over the forecast period (2024-2031). Internet of Things (IoT) refers to the network of connected devices over the internet that are embedded with sensors and software. Growing adoption of automation around the world and advancements in connected device technologies are forecasted to be key factors driving the Internet of Things (IoT) market growth in the future.

Download a detailed overview:
https://www.skyquestt.com/report/internet-of-things-market
Browse in-depth TOC on “Internet of Things (IoT) Market”
Pages – 197Tables – 69Figures – 75Internet of Things (IoT) Market Overview:
Report Coverage
Details
Market Revenue in 2023
$ 380.6 billion
Estimated Value by 2031
$1572.37 billion
Growth Rate
Poised to grow at a CAGR of 19.4%
Forecast Period
2024–2031
Forecast Units
Value (USD Billion)
Report Coverage
Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
Segments Covered
Component Type, Application, and Region
Geographies Covered
North America, Europe, Asia Pacific, and the Rest of the world
Report Highlights
Updated financial information / product portfolio of players
Key Market Opportunities
Rising demand for connected healthcare and growing use of industrial automation solutions
Key Market Drivers
Advancements in connectivity and connected device technologies
 
 
Hardware is Estimated to Dominate the Global Market Share Owing to High Use of Hardware Components in IoT
Hardware components such as sensors and actuators are highly vital to the proper functioning of any kind of Internet of Things (IoT) device. Growing adoption of IoT devices in different industry verticals for various applications is promoting market growth via this segment. The development of new hardware solutions also helps this segment maintain its dominance.
Smart Agriculture is the Fastest-growing Segment Owing to Rising Adoption of Precision Agriculture Practice
Rising emphasis on improving agricultural yield and sustainability has resulted in the growing adoption of smart agriculture and precision agriculture practices. IoT devices play a crucial role in monitoring and controlling different elements of a smart agriculture setup that is mostly automated using different smart devices thereby contributing to the IoT market growth as well.
Growing Adoption of 5G Technology Allowing North America to Dominate the Global Internet of Things (IoT) Market
Rapid adoption of 5G technology and high use of cloud-based platforms are key factors allowing North America to lead the demand for Internet of Things (IoT) around the world. Surging investments in the research and development of advanced technologies and the presence of key tech giants such as Amazon, Google, IBM, and Microsoft also helps the dominance of this region. Canada and the United States remain the most lucrative markets for Internet of Things (IoT) companies in North America through 2031.
Request Free Customization of this report:
https://www.skyquestt.com/speak-with-analyst/internet-of-things-market
Internet of Things (IoT) Market Insights:
Drivers
Advancements in connectivity and connected device technologies.Growing demand for Industrial IoT (IIoT) solutions.Increasing number of smart cities and development of smart infrastructure.Restraints
Lack of standardization of IoT devices and technologies.Privacy and data security issues.Interoperability challenges and complex integration scenarios.Prominent Players in Internet of Things (IoT) Market
MicrosoftCisco SystemsIntelSiemens (Germany)AWS (US)Oracle (US)Qualcomm (UK)SAP (Germany)IBM (US)Google (US)View report summary and Table of Contents (TOC):
https://www.skyquestt.com/report/internet-of-things-market
Key Questions Answered in Internet of Things (IoT) Market Report
What are the top drivers for Internet of Things (IoT) market going forward?Who are the leading Internet of Things (IoT) market players?Where will demand for Internet of Things (IoT) be high?Which component accounts for a dominant revenue share of the global Internet of Things (IoT) market?This report provides the following insights:
Analysis of key drivers (advancements in connectivity and connected device technologies, growing demand for industrial IoT (IIoT), development of smart infrastructure for smart cities, growing use of smart devices ), restraints (lack of standardization, complexities in integration, concerns regarding security and privacy of data), and opportunities (rising popularity of connected healthcare, increasing adoption of Industry 4.0, rising use of industrial automation), influencing the growth of Internet of Things (IoT) market.Market Penetration: All-inclusive analysis of product portfolio of different market players and status of new product launches.Product Development/Innovation: Elaborate assessment of R&D activities, new product development, and upcoming trends of the Internet of Things (IoT) market.Market Development: Detailed analysis of potential regions where the market has potential to grow.Market Diversification: Comprehensive assessment of new product launches, recent developments, and emerging regional markets.Competitive Landscape: Detailed analysis of growth strategies, revenue analysis, and product innovation by new and established market players.Related Reports:
Global Internet of Things in Retail Market
Global Internet of Things (IoT) in Agriculture Market
Global Internet of Things (IoT) Microcontroller Market
Global IOT In Healthcare Market
Global IOT in Manufacturing Market
About Us:
SkyQuest is an IP focused Research and Investment Bank and Accelerator of Technology and assets. We provide access to technologies, markets and finance across sectors viz. Life Sciences, CleanTech, AgriTech, NanoTech and Information & Communication Technology.
We work closely with innovators, inventors, innovation seekers, entrepreneurs, companies and investors alike in leveraging external sources of R&D. Moreover, we help them in optimizing the economic potential of their intellectual assets. Our experiences with innovation management and commercialization has expanded our reach across North America, Europe, ASEAN and Asia Pacific. 
Contact:
Mr. Jagraj Singh Skyquest Technology1 Apache Way,Westford,Massachusetts 01886USA (+1) 351-333-4748Email: [email protected] Our Website: https://www.skyquestt.com/

View original content:https://www.prnewswire.co.uk/news-releases/internet-of-things-iot-market-to-expand-at-a-stellar-19-4-cagr-through-2031–skyquest-technology-302127239.html

Continue Reading

Artificial Intelligence

Sapiens Unveils Enhanced Reinsurance and Analytics Solution Catering to Evolving Market Demands

Published

on

sapiens-unveils-enhanced-reinsurance-and-analytics-solution-catering-to-evolving-market-demands

Latest version enhances operational efficiency, regulatory reporting, and strategic decision-making with robust business insights
ROCHELLE PARK, N.J., April 25, 2024 /PRNewswire/ — Sapiens International Corporation, (NASDAQ: SPNS) (TASE: SPNS), a leading global provider of software solutions for the insurance industry, today announced the launch of its latest version of Sapiens ReinsuranceMaster.

The new release of Version 9 brings a multitude of enhancements and technology stack updates, designed to empower insurers and reinsurers with robust, enriched functionality to support business requirements. This includes automating global inter-company retrocession, facilitating U.S. NAIC statutory reporting (Schedule F), and real-time reinsurance allocation support (‘reinsurance as a service’).
The latest release offers a multitude of enhancements, with one of the standout features being the seamless integration of Sapiens Intelligence with Sapiens ReinsuranceMaster. This integration empowers users with advanced data capabilities and actionable insights through out-of-the-box reinsurance reports and analytics of the reinsurance portfolio’s performance.
In addition, the new release brings significant improvements to the user experience, with a revamped user interface, enhancements in processing performance through improvements and parallel processing mechanisms, improved scalability and operability. 
“With the growing significance of reinsurance in today’s volatile environment, our latest version of Sapiens ReinsuranceMaster with Sapiens Intelligence offers even greater value to insurers and reinsurers, catering to the ever-changing demands of this dynamic market,” said Roni Al-Dor, Sapiens President & CEO. “Leveraging the shared experience from our other products as well as requirements from our global client base, the solution is now very well-positioned to support global automation of complex reinsurance programs and provide management with insights into reinsurance performance as well as statutory reporting.”  
Sapiens ReinsuranceMaster is a comprehensive, single platform for large and multi-national reinsurance programs, providing full financial control and flexibility across all lines of business. The solution supports the entire range of reinsurance contracts, providing full support for all auditing requirements and a consolidated view of liabilities and risks, as well as helping prevent financial leakage.
Sapiens Intelligence, now a fully integrated component of Sapiens ReinsuranceMaster v.9, produces actionable insights to maximize the value of data and KPIs for smarter decision making, improving reinsurance business management.
About Sapiens  
Sapiens International Corporation (NASDAQ and TASE: SPNS) empowers the financial sector, with a focus on insurance, to transform and become digital, innovative, and agile. With more than 40 years of industry expertise, Sapiens’ cloud-based SaaS insurance platform offers pre-integrated, low-code capabilities across core, data, and digital domains to accelerate our customers’ digital transformation. Serving over 600 customers in more than 30 countries, Sapiens offers insurers across property and casualty, workers’ compensation, and life insurance markets the most comprehensive set of solutions, from core to complementary, including Reinsurance, Financial & Compliance, Data & Analytics, Digital, and Decision Management. For more information visit https://sapiens.com or follow us on LinkedIn  
Investor and Media Contact : Yaffa Cohen-Ifrah Sapiens Chief Marketing Officer and Head of Investor Relations Email: [email protected] 
Forward Looking Statements
Certain matters discussed in this press release that are incorporated herein and therein by reference are forward-looking statements within the meaning of Section 27A of the Securities Act, Section 21E of the Exchange Act and the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, that are based on our beliefs, assumptions and expectations, as well as information currently available to us. Such forward-looking statements may be identified by the use of the words “anticipate,” “believe,” “estimate,” “expect,” “may,” “will,” “plan” and similar expressions. Such statements reflect our current views with respect to future events and are subject to certain risks and uncertainties. There are important factors that could cause our actual results, levels of activity, performance or achievements to differ materially from the results, levels of activity, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to:  the degree of our success in our plans to leverage our global footprint to grow our sales; the degree of our success in integrating the companies that we have acquired through the implementation of our M&A growth strategy; the lengthy development cycles for our solutions, which may frustrate our ability to realize revenues and/or profits from our potential new solutions; our lengthy and complex sales cycles, which do not always result in the realization of revenues; the degree of our success in retaining our existing customers or competing effectively for greater market share; the global macroeconomic environment, including headwinds caused by inflation, relatively high interest rates, potentially unfavorable currency exchange rate movements, and uncertain economic conditions, and their impact on our revenues, profitability and cash flows; difficulties in successfully planning and managing changes in the size of our operations; the frequency of the long-term, large, complex projects that we perform that involve complex estimates of project costs and profit margins, which sometimes change mid-stream; the challenges and potential liability that heightened privacy laws and regulations pose to our business; occasional disputes with clients, which may adversely impact our results of operations and our reputation; various intellectual property issues related to our business; potential unanticipated product vulnerabilities or cybersecurity breaches of our or our customers’ systems; risks related to the insurance industry in which our clients operate; risks associated with our global sales and operations, such as changes in regulatory requirements, wide-spread viruses and epidemics like the coronavirus epidemic,  and fluctuations in currency exchange rates; and risks related to our principal location in Israel and our status as a Cayman Islands company.
While we believe such forward-looking statements are based on reasonable assumptions, should one or more of the underlying assumptions prove incorrect, or these risks or uncertainties materialize, our actual results may differ materially from those expressed or implied by the forward-looking statements. Please read the risks discussed under the heading “Risk Factors” in our Annual Report on Form 20-F for the year ended December 31, 2023, to be filed in the near future, in order to review conditions that we believe could cause actual results to differ materially from those contemplated by the forward-looking statements. You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that future results, levels of activity, performance and events and circumstances reflected in the forward-looking statements will be achieved or will occur. Except as required by law, we undertake no obligation to update publicly any forward-looking statements for any reason, to conform these statements to actual results or to changes in our expectations.
 
Logo: http://mma.prnewswire.com/media/585787/Sapiens_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/sapiens-unveils-enhanced-reinsurance-and-analytics-solution-catering-to-evolving-market-demands-302127409.html

Continue Reading

Trending